Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma

JUYOUN JIN1,2*, KYEUNG MIN JOO2,3*, SE JEONG LEE1,2, MI-YOUNG JO1,2, YONGHYUN KIM1,2, YOUNGGEON JIN1,2, JOONG KYU KIM1, MI-MI AHN4, MI-JUNG YOON4, JAESEUNG LIM4 and DO-HYUN NAM 1,2*

1Department of Neurosurgery, 2Cancer Stem Cell Research Center, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, #50 Irwon-dong, Gangnam-Gu, Seoul 135-710; 3Department of Anatomy, Seoul National University College of Medicine, #28 Yeongone-dong, Jongno-gu, Seoul 110-799; 4Innocell Corporation, SJ Technoville, 60-19 Gasandong, Geumcheongu, Seoul 153-769, Korea

Received March 1, 2010; Accepted April 22, 2010

DOI: 10.3892/or_00001038

Abstract. The presence of active immunity within the brain supports the possibility of effective immunotherapy for glioblastoma (GBM). To provide a clinically-relevant adoptive immunotherapy for GBM using ex vivo expanded cytokine-induced killer (CIK) cells, the treatment capability of CIK cells, either alone or in combination with temozolomide (TMZ) were evaluated. Human CIK (hCIK) cells were cultured from PBMC using activating anti-CD3 antibody and IL-2, which were 99% CD3+, 91% CD3+CD8+ and 29% CD3+CD56+. In vitro, hCIK cells showed tumor-specific cytotoxicity against U-87MG human GBM cells. When hCIK cells were injected into tail veins of immune-compromised mice bearing U-87MG tumors in their brains, numerous CIK cells infiltrated into the brain tumors. CIK treatments (1x10^5, 1x10^6 or 1x10^7, once a week for four weeks) inhibited the tumor growth significantly in a dose-dependent manner; 44, 54 and 72% tumor volume reduction, respectively, compared with the control group (P<0.05). Moreover, hCIK cells (1x10^7, once a week for four weeks) and TMZ (2.5 mg/kg, daily for 5 days) combination treatment further increased tumor cell apoptosis and decreased tumor cell proliferation and vessel density (P<0.05), creating a more potent therapeutic effect (95% reduction in tumor volume) compared with either hCIK cells or TMZ single therapy (72% for both, P<0.05). Taken together, CIK cell-immunotherapy and TMZ chemotherapy have synergistic therapeutic effects and could be combined for a successful treatment of GBM.

Introduction

Glioblastoma (GBM) is the most common primary malignant brain tumor. Despite multidisciplinary treatment approaches, prognosis and survival for patients with GBM remains poor (1). Traditionally, the brain has long been considered as an immunologically privileged organ because of the blood-brain barrier (2). However, increased awareness of the interplay between the brain and the immune system (3) and the presence of active immunity within the brain support the possibility of effective immunotherapy for GBM.

The goal of immune cell-based cancer therapy is to eliminate cancer cells through the transfer of ex vivo expanded active immune cells. Various immune cell types such as dendritic cells, lymphokine-activated killer (LAK) cells, natural killer (NK) cells, cytotoxic T cells and cytokine-induced killer (CIK) cells have been studied as a potential candidate for effective immunotherapy (4-8). Among them, CIK cells, characterized by the co-expression of CD3 and CD56 molecules, demonstrated potent cytolytic activity in a MHC-unrestricted manner (4,5). In addition, CIK cells are most clinically applicable since CIK cells are readily expandable from peripheral blood mononuclear cells (PBMC) of cancer patients (6).

Two previous studies showed that CIK cells have significant therapeutic effects against GBM in vivo (7,8). However, intracranial CIK cell injection method (7) and results from subcutaneous GBM xenograft animal model (8) are difficult to translate immediately into the clinical settings. Combinational effects with temozolomide (TMZ) also need to be considered since it is the most widely-used chemotherapeutic agent against GBM in the clinic. Accordingly, we utilized U-87MG GBM orthotopic xenograft animal models and evaluated anti-tumor effects of CIK cells with intravenous injection. CIK cells showed significant therapeutic effects against GBM, and it was potentiated by the combination with TMZ.
Materials and methods

Generation of human and mouse CIK cells. Human cytokine-induced killer (hCIK) cells were generated from PBMC of healthy donors (8-12). PBMC cultured in lymphomedia (Lymphotech, Japan) containing 10% FBS (Invitrogen, CA, USA), immobilized anti-CD3 antibody (5 mg/ml, BD Pharmingen, NJ, USA) and recombinant human interleukin-2 (IL-2; 700 U/ml, R&D Systems, MN, USA) for five days. The cell suspension were further incubated in a fresh media containing only recombinant human IL-2 (170 U/ml) for nine days. Mouse CIK (mCIK) cells were generated from spleens of GFP transgenic C57BL/6 mouse [C57BL/6-Tg (UBC-GFP) 30 Scha/J, The Jackson Laboratory, Bar Harbor, ME] (13). Expansion of mCIK cells was performed as described above.

Phenotype analysis of human and mouse CIK cells. Fresh PBMC and expanded hCIK cells were analyzed with appropriate monoclonal antibodies (CD3-FITC, CD4-FITC, CD8-PE, CD56-PC5 and CD25-PE, Beckman Coulter, Fullerton, USA). Fluorescence-activated cell sorting analyses was performed on a FACS Calibur flow cytometer (BD Biosciences, CA, USA) as described previously (8,10-12). mCIK phenotype analysis was performed in a similar manner using CD3-PerCP, CD4-FITC, CD8-PE, NKG2D-PECy7, and CD25-PE (BD Pharmingen).

Cell culture. U-87MG human GBM cells (ATCC) were grown in EMEM supplemented with 10% FBS, 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 μg/ml). The murine GBM cell line GL26 (H-2b) was kindly provided by Dr John S. Yu (Cedars Sinai Medical Center, Los Angeles, CA, USA). GL26 cells were cultured in RPMI-1640 supplemented with 10% FBS.

In vitro cytotoxic activity of hCIK cells. The human cancer cell lysis by hCIK cells was detected by the release of lactate dehydrogenase (LDH) using CytoTox 96 non-radioactive cytotoxicity assay according to the manufacturer’s instructions (Promega, USA) (14). Briefly, CIK cells were added at specified effector-to-target (E:T) ratios (10:1 to 30:1) and incubated for 4 h. The absorbance was measured at 490 nm using a Multiscan MS microplate reader (LabSystem, Helsinki, Finland). Specific cytotoxicity was calculated as in previous studies (14).

GBM orthotopic animal model. Animal experiments were approved by the appropriate Institutional Review Boards of the Samsung Medical Center (Seoul, Korea) and conducted in accord with the ‘National Institute of Health Guide for the Care and Use of Laboratory Animals’ (NIH publication no. 80-23, revised in 1996). For orthotopic GBM model, anesthetized 6-week-old male Balb/c-nu (for U-87MG human GBM cells) and C57BL/6 (H-2b, for GL26 murine GBM cells) mice were secured in a rodent stereotactic frame. A hollow guide screw was implanted into a small drill hole made at 2 mm left and 1 mm anterior to the bregma, and 2x10^5 U-87MG cells in 5 μl HBSS or 1x10^5 GL26 cells were injected through this guide screw into the white matter at a depth of 2 mm [anterior/posterior (AP) +0.5 mm, medial/lateral (ML) +1.7 mm, dorsal/ventral (DV) -3.2 mm].

In vivo anti-tumor activities of hCIK cells in an orthotopic xenograft model. hCIK cells (1x10^5, 1x10^6 or 1x10^7, in 100 μl HBSS) were injected intravenously into animals bearing U-87MG tumor in their brains once a week for four weeks (Fig. 4A). One day after the last injection of hCIK cells,
brains were harvested and processed for paraffin embedding. The tumor volume was calculated by measuring the section with the largest tumor portion and applying the formula: \((\text{width}^2 \times \text{length}) \times 0.5\). For detection of hCIK cells in brain tumor sections, the mouse anti-human CD3 monoclonal antibody (Dako, USA) was used as the primary antibody (15).

In vivo tracking of mCIK cells in an orthotopic syngenic model. GL26 tumor-bearing animals were injected with \(1 \times 10^8\) of GFP+-mCIK cells (Fig. 3B). Two or nine days after the cell transfer, tumor-bearing mice were sacrificed and their blood, lymph node, spleen, lung, liver, brain and brain tumor were harvested. GFP-expressing cells were detected by FACS Calibur flow cytometer or immunohistochemistry using the mouse anti-GFP monoclonal antibody (Chemicon International, Temecula, CA) and the Alexa 488-labeled goat anti-mouse IgG (1:200, Invitrogen) (15).

In vivo therapeutic effects of combination treatment of hCIK cells and TMZ in an orthotopic xenograft model. hCIK cells (1x10⁷, in 100 μl HBSS) were injected intravenously into animals bearing U-87MG tumor in their brains once a week for four weeks, either alone or with intraperitoneal daily administration of 2.5 mg/kg TMZ (in 100 μl saline) from 21 to 25 days after the tumor cell implantation (Fig. 5A). One day after the last injection, brains were harvested and processed for paraffin embedding. The tumor volume was calculated as described above.

Immunohistochemistry against PCNA and CD31 was performed as described previously (15). The mouse anti-PCNA (PC10, Dako) and mouse anti-CD31/PECAM-1 (BD Pharmingen) antibody were utilized. TUNEL assay was performed by the DeadEnd fluorometric TUNEL system (Promega). For the quantification, the number of stained cells was counted in ten random fields for each animal.

Statistical analyses. Statistical comparisons between groups were performed using Student’s t-test, one-way ANOVA or multiple comparison tests. \(P<0.05\) was considered statistically significant.

Results

In vitro expansion of hCIK cells from human PBMC. hCIK cells cultured from human PBMC (hPBMC) using immobilized anti-CD3 antibody and recombinant human IL-2 for two weeks were 99% CD3+, 91% CD3+CD8+ and 29% CD3+CD56+ in flow cytometric analysis (Fig. 1A), which is consistent with the previous studies (10-12). Compared with fresh hPBMC, CD3+CD8+ and CD3+CD56+ cell ratio increased dramatically, while CD4+ cell ratio decreased (\(^{**}P<0.001\); Fig. 1B).

Figure 3. hCIK cells inhibit GBM tumor growth in an orthotopic xenograft model. (A) The timeline for the assessment of in vivo anti-tumor activities of hCIK cells in an orthotopic xenograft model. (B) hCIK cells reduced U-87MG tumor volumes in a dose-dependent manner. Data are expressed as the mean ± SE. \(*P<0.05\). (C) hCIK cells were traced by immunohistochemistry using a human CD3 specific antibody. Arrowheads = CD3-positive hCIK cells in the tumor bed.
In vitro toxicity of hCIK cells against human GBM cells. U-87MG human GBM cells were co-cultured with hCIK cells or fresh hPBMC [effector-to-target (E:T) ratio=10:1 and 30:1] and in vitro cytotoxic activities of cultured hCIK cells were evaluated by the LDH assay. At E:T ratios of 10:1 and 30:1, hCIK cells destroyed 20%, and 42% of U-87MG cells, respectively (**P<0.001; Fig. 2). In contrast, only <3% of cancer cells were destroyed by fresh hPBMC.

In vivo therapeutic effect of hCIK cells against GBM. Next, in vivo therapeutic efficacy of hCIK cells against GBM was determined; 1x10^5, 1x10^6 or 1x10^7 hCIK cells (in 100 μl HBSS) were injected intravenously into animals bearing U-87MG tumor in their brains once a week for four weeks (control = HBSS only, each group n=7; Fig. 3A). The tumor volumes were determined one day after the last hCIK cell injection. Treatment with hCIK cells significantly inhibited U-87MG tumor growth in a dose-dependent manner; 1x10^5, 1x10^6 and 1x10^7 groups showed 44, 54 and 72% tumor volume reduction, respectively, compared with the control group (**P<0.005 vs. control, Fig. 3B). A number of hCIK cells were identified dose-dependently in the tumor bed by specific anti-human CD3 antibody (Fig. 3C), confirming the direct contact between hCIK and GBM cells in the brain.

Infiltration of syngeneic CIK cells into GBM in the brain. Infiltration of hCIK cells into the brain tumor could be a specific phenomenon in the immune-compromised host. To exclude this possibility, we cultured mouse CIK (mCIK) cells from PBMC of GFP transgenic mice (C57BL/6 background) and injected them into the veins of C57BL/6 mice harboring GL26 GBM (GBM cell line originated from C57BL/6) tumor mass in their brains. Cultured GFP+-mCIK cells showed similar surface molecular profiles with hCIK cell population (Fig. 4A; 82% CD3+CD8+, 95% CD3+NKG2D+). When the injected GFP+-mCIK cells were tracked in blood, brain tumor, and other organs at two days after the injection by flow cytometric analysis (n=5, Fig. 4B), GFP+-mCIK cells were concentrated in brain tumors (% GFP+ cells in tissue lymphocytes, Fig. 4C). The ratio further increased nine days after the injection (n=5) compared to day 2 (***P<0.005; Fig. 4C), suggesting continuous infiltration of CIK cells. GFP+ mCIK cells in GBM was confirmed by the immunohistochemical method (Fig. 4D).

Immunotherapy using hCIK cells potentiates anti-tumor effect of TMZ. In vivo therapeutic effects of combination treatment of hCIK cells and TMZ were evaluated by tumor mass volume (Fig. 5A). hCIK cells (1x10^7, in 100 μl HBSS) were injected intravenously into animals bearing U-87MG tumor in their brains once a week for four weeks, either alone or with intraperitoneal daily administration of 2.5 mg/kg TMZ (in 100 μl saline) from 21 to 25 days after the tumor cell implantation (control = 100 μl HBSS + normal saline, n=7;
and \( P<0.001 \) vs. control, \( +P<0.05 \) vs. single agent. The group (\( ***P=0.0001 \)) was also significantly smaller than the control group showed 95% smaller tumor volume than that of control for both monotherapies, showing significant reduction of the tumor volumes (72% smaller than that of the control group for both monotherapies, \( P<0.05 \)), the combination of hCIK cells and TMZ created additive or synergistic therapeutic effects; hCIK + TMZ created additive or synergistic therapeutic effects in the U-87MG human GBM animal model. Data are expressed as the mean ± SE. *\( P<0.05 \), \( +P<0.0021 \); Fig. 5B).

**Discussion**

Recently, CIK cells were reported to inhibit growth of GBM in 1) intratumoral injection of hCIK cells in the orthotopic GBM xenograft models and in 2) intravenous injection of hCIK cells in the subcutaneous GBM xenograft models (7,8). In this study, the therapeutic effects of CIK cells against GBM were tested in a more clinically-relevant setting: U-87MG GBM orthotopic xenograft model and intravenous injection of hCIK cells. hCIK cells, either alone or in combination with TMZ, demonstrated significant treatment effects against GBM, confirming their effects.

TMZ is an indispensable treatment modality for GBM since it is the sole chemotherapeutic agent that has been proved to lengthen the survival of GBM patients (16). Therefore, the therapeutic efficacy of newly-developed immunotherapy need to be compared with TMZ, or combination treatment with TMZ should be investigated to prove the usefulness of the immunotherapy (17). For the first time, we showed that immunotherapy using CIK cells possess similar therapeutic effects to TMZ and that it can potentiate the effects of TMZ in an additive or synergistic manner. Our results, therefore, increased the clinical relevance of CIK cells further.

We previously reported that TMZ significantly decreased the number of PCNA-positive proliferating tumor cells and increased the number of TUNEL-positive apoptotic tumor cells in an orthotopic GBM xenograft model (18,19). In this study, we found that hCIK cells potentiate the effects of TMZ on the proliferation, apoptosis, and vascularization of GBM cells significantly, which suggest that hCIK cells and TMZ cumulatively enhance the inhibition of cell proliferation and tumor vascularization and the stimulation of apoptosis.

Anti-tumor mechanisms of CIK cells include the secretion of cytotoxic molecules such as granzyme and perforin, the activation of Fas signaling pathway of tumor cells, and the production of multiple cytokines regulating the immune response system (14,20). Therefore, direct interactions between hCIK cells and tumor cells are essential. In the present study, we confirmed the infiltration of CIK cells into GBMs of the brain in both immune-compromised GBM xenograft animal model and immune-competent syngenic GBM animal model. CIK cells introduced systemically were accumulated in the brain tumor preferentially compared with other organs such as blood, lymph node, spleen, lung, liver and normal brain parenchyma. These results strongly suggest that the adoptively transferred CIK cells harbor tumor-trophic capacities. Tracking of CIK cells would also be useful to elucidate anti-tumor mechanisms more clearly and to provide a basis for novel modalities with enhanced anti-tumor capacities (21).

Traditionally, hPBMC are incubated in a medium containing IFN-\( \gamma \), IL-18 and/or TNF-\( \alpha \) to increase cytotoxicity of CIK cells (6,22-27). However, we optimized the traditional...
protocol economically and generated hCIK cells without those cytokines. Our optimized protocol also shortened the incubation time from 3-4 weeks to 2 weeks (12). In this study, we generated sufficient CD3+CD4-CD8+CD56+ and CD3+CD4-CD8-CD56+ cells with a more economical protocol and confirmed their anti-tumor activities against GBM in vitro and in vivo. These improvements would enable more facile translation to the clinical setting.

LAK cells (in combination with IL-2) eliciting a general systemic immune response in the spleen (21) was previously suggested to be a possible therapy against glioma (28). However, LAK cells have several disadvantages as an immunotherapeutic agent, such as poor cytotoxicity, short in vivo half-life, and numerous side effects (29,30). Regarding specific targeting to tumor site, potent direct cytotoxic effects including both the specific anti-tumor effects of T cells and the non-MHC-restricted anti-tumor advantage of NK cells and synergistic effects with TMZ, CIK cells could be a more feasible immunotherapeutic agent.

In summary, we provide a clinically-relevant adoptive immunotherapy for GBM using CIK cells. The treatment capability of CIK cells, either alone or in combination with TMZ could be directly translated to clinical trials.

Acknowledgements

This study was supported by the Korea Research Foundation Grant funded by the Korean Government (KRF-2008-313-E00234), a grant from the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare Affairs, Republic of Korea (A092255), and the Samsung Biomedical Research Institute grant, no. SBRI C-B0-218-1.

References


